Avoid common mistakes on your manuscript.
The original version of this article [1] unfortunately contained mistakes to the figure legends and was missing Figure 7 (Fig. 1 here). The corrected legends are as follows:
Fig. 1 Experimental Protocol design.
Fig. 2 Effect of NaHS on blood glucose level in STZ treated rats. a P < 0.05 versus vehicle treated, b P < 0.05 versus [STZ (45)] treated group, c P < 0.05 versus [STZ (45) + NaHS (10)] treated group, d P < 0.05 versus [STZ (45) + NaHS (30)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.
Fig. 3 Effect of NaHS and losartan on Lipid Peroxidation in STZ treated rats. a P < 0.05 versus vehicle treated, b P < 0.05 versus [STZ (45)] treated group, c P < 0.05 versus [STZ (45) + NaHS (10)] treated group, d P < 0.05 versus [STZ (45) + NaHS (30)] treated group, e P < 0.05 versus [STZ (45) + LOS (5)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.
Fig. 4 Effect of NaHS and losartan on Reduced Glutathione in STZ treated rats. a P < 0.05 versus vehicle treated, b P < 0.05 versus [STZ (45)] treated group, c P < 0.05 versus [STZ (45) + NaHS (10)] treated group, d P < 0.05 versus [STZ (45) + NaHS (30)] treated group, e P < 0.05 versus [STZ (45) + LOS (5)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.
Fig. 5 Effect of NaHS and losartan on Nitrite in STZ treated rats. a P < 0.05 versus vehicle treated, b P < 0.05 versus [STZ (45)] treated group, c P < 0.05 versus [STZ (45) + NaHS (10)] treated group, d P < 0.05 versus [STZ (45) + NaHS (30)] treated group, e P < 0.05 versus [STZ (45) + LOS (5)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.
Fig. 6 Effect of NaHS and losartan on MABP in STZ treated rats. a P < 0.05 versus vehicle treated, b P < 0.05 versus [STZ (45)] treated group, c P < 0.05 versus [STZ (45) + NaHS (10)] treated group, d P < 0.05 versus [STZ (45) + NaHS (30)] treated group, e P < 0.05 versus [STZ (45) + LOS (5)] treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine.
The missing figure can be found below, with the correct figure legend:
Hemotoxylin-Eosin stained longitudinal section of kidneys (10×). a Normal control, b STZ treated group (45), c NaHS (30), d DL-p (10) + NaHS (30), e LOS, f NaHS (10) + Losartan (5)
Reference
Kaur M, Sachdeva S, Bedi O, Kaur T, Kumar P. Combined effect of hydroden sulphide donor and losartan in experimental diabetic nephropathy in rats. J Diabetes Metab Disord. 2015;14:63. doi:https://doi.org/10.1186/s40200-015-0185-7.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:https://doi.org/10.1186/s40200-015-0185-7.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Kaur, M., Sachdeva, S., Bedi, O. et al. Erratum to: Combined effect of hydrogen sulphide donor and losartan in experimental diabetic nephropathy in rats. J Diabetes Metab Disord 14, 80 (2015). https://doi.org/10.1186/s40200-015-0212-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s40200-015-0212-8